PharmacovigilanceOfficial

AIFA starts rolling review of daraxonrasib after positive CHMP opinion in pancreatic cancer

🇮🇹 AIFA · Wed 18 Nov 2026

Italy's medicines agency has begun a progressive assessment of available data on daraxonrasib, mirroring the EMA's approach, to speed access for eligible metastatic pancreatic cancer patients.

The Italian Medicines Agency (AIFA) said on 18 November 2026 that it is already evaluating daraxonrasib, a medicine that has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Official source: AIFA ↗

Article written by VigiEye from the official source (AIFA). AI-assisted; check the source before acting.